Sandoz Canada puts out new MS treatment
by CM Staff
The new product will be covered by Sandoz Continüm Patient Support Program, which is working with a network of clinics specialized in multiple sclerosis treatments.
BOUCHERVILLE — Sandoz Canada announced on October 4th, the launch of PrSandoz Dimethyl Fumarate Delayed-Release Capsules, a generic equivalent to Biogen Canada’s PrTecfidera. It is indicated as a monotherapy for the treatment of relapsing remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of disability.
PrSandoz Dimethyl Fumarate Delayed-Release Capsules is available in a blister pack of 56 capsules in two strengths (120 mg and 240 mg.) The packaging includes indicators to help consumers track medication usage during the week.
The new product will be covered by Sandoz Continüm Patient Support Program, which is already working with a network of clinics specialized in multiple sclerosis treatment across Canada. The program will include services to help patients get reimbursement from insurers, financial assistance, and educational material for pharmacists serving patients who take Dimethyl Fumarate Delayed Release Capsules.
“Relapsing remitting multiple sclerosis is a severe chronic condition. With this second MS treatment in our portfolio, we are continuing our mission to make life-enhancing medicines more accessible by launching quality generics and providing the best possible support to patients and healthcare professionals,” said Michel Robidoux, President and General Manager of Sandoz Canada, in a company press release.
